HY2CARE BV
Desconocido
ACTIVE: Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective
HY2CARE BV
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2022-ACCELERATOR-01
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. T...
2022-11-11 - 2024-09-30 | Financiado
2022-11-11 - 2024-09-30 | Financiado
Hy2Care: INJECTABLE HYDROGELS FOR CARTILAGE REPAIR
HY2CARE BV
tramitó un
H2020:
H2020-SMEInst-2016-2017
Hy2Care BV is a spin-off company of Twente University, in the Netherlands. It is Hy2Care’s ambition to introduce the first cure to Osteoarth...
2016-05-04 - 2016-11-30 | Financiado
2016-05-04 - 2016-11-30 | Financiado
FutForm: Future Formulations Developing Future Pharmaceuticals Through Advanced Analysis and Intersectoral E...
HY2CARE BV
participó en un
H2020:
H2020-MSCA-RISE-2015
The estimated cost of getting a new medicine to market is now in excess of $2.6 billion, with an additional $300 million (approx.) typically...
2015-10-28 - 2020-03-31 | Financiado
2015-10-28 - 2020-03-31 | Financiado
* No se disponen de datos de la empresa actual.